Policy & Regulation

Eli Lilly Just Spent $7.8 Billion to Own the Future of Sleep Medicine — And It Is Funding This With Ozempic Money

By BHC, Editor in Chief · April 6 · 5 min read

BHC, Editor in Chief — Eli Lilly Just Spent $7.8 Billion to Own the Future of Sleep Medicine — And It Is Funding This With Ozempic Money

Summary

  • Eli Lilly has agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, adding sleep disorder and neuroscience drugs to its portfolio. Here is why this deal matters globally and what it signals for Indian pharma.

Eli Lilly has announced a definitive agreement to acquire Centessa Pharmaceuticals — a clinical-stage company developing a new class of drugs for sleep-wake disorders and neurological conditions — in a deal worth up to $7.8 billion. Lilly will pay $38 per share in cash upfront, valuing Centessa at approximately $6.3 billion, with an additional $9 per share in contingent value rights that could add up to $1.5 billion more if Centessa's lead drug clears specific US regulatory milestones. The deal was announced on March 31, 2026, and is expected to close in the third quarter of the year.

"By combining Centessa's team and capabilities with Lilly's global research, clinical, regulatory, and commercial capabilities, we will seek to accelerate the orexin portfolio across a broad range of neuroscience indications."

The acquisition is the latest in a string of major deals Lilly has pursued since its GLP-1 drugs Zepbound and Mounjaro generated extraordinary revenue. In 2026 alone, Lilly has acquired Ventyx Biosciences for $1.2 billion, agreed to acquire Orna Therapeutics for $2.4 billion, and signed an $8.8 billion collaboration with China-based Innovent for cancer and immune disorder therapies. The Centessa deal is the most expensive yet — and it buys Lilly something specific: leadership in the orexin neuroscience space before the field matures.

**What Centessa Is Building and Why It Matters

Centessa Pharmaceuticals is developing orexin receptor 2 (OX2R) agonists — a class of drugs that modulate the brain's orexin system, which governs the sleep-wake cycle. The company's lead candidate, cleminorexton (formerly ORX750), has shown a potential best-in-class profile in Phase 2a clinical studies across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia — three conditions characterised by excessive daytime sleepiness and impaired wakefulness that significantly reduce quality of life.

Orexin is not a niche opportunity. Beyond narcolepsy and sleep disorders, there is growing scientific evidence that orexin system dysfunction plays a role in Alzheimer's disease, depression, and other neurological and neuropsychiatric conditions. Lilly is not buying a narrow sleep drug — it is buying a platform for neurological medicine that could eventually address some of the most challenging conditions in human health.

**The Competitive Context

Centessa is not the only player in orexin agonists. Takeda is furthest ahead: in February 2026, the FDA accepted Takeda's New Drug Application and granted Priority Review for its own orexin agonist. Jazz Pharmaceuticals' sodium oxybate already ranks among the top-selling treatments for excessive daytime sleepiness in narcolepsy. The market exists, it is commercially validated, and it is about to get significantly more competitive. Lilly is buying Centessa now — before cleminorexton's approval, expected no earlier than 2028 — because the cost of acquisition will only increase once clinical validation is complete.

**The GLP-1 Wealth Effect on Global Pharma M&A

The Centessa deal is part of a larger story that every pharma founder, investor, and hospital administrator should understand. Lilly's GLP-1 franchise has generated cash flows that have fundamentally changed the company's strategic options. Rather than returning capital to shareholders or sitting on the balance sheet, Lilly is using that cash to acquire clinical-stage companies across neuroscience, immunology, and oncology — building a portfolio that will sustain it for the next two decades.

This pattern — blockbuster drug cash funding diversified acquisition strategies — is one of the primary drivers of global healthcare M&A in 2026. Indian pharma companies, particularly those with strong generics cash flows, are watching this playbook and beginning to execute their own versions: Torrent Pharma's acquisition of JB Chemicals, Sun Pharma's consistent international M&A, and Dr Reddy's global expansion all reflect variants of the same strategy.

**Implications for Indian Pharma

India's generic pharmaceutical industry has a specific intersection with the Centessa story. Generic orexin agonists will eventually enter markets globally — and Indian manufacturers will be among the first movers when patent protection expires. Companies like Dr Reddy's, Sun Pharma, and Zydus, which have already demonstrated capability in complex CNS generics, should be tracking the orexin pipeline closely.

More broadly, the scale of Lilly's acquisition activity signals that the global pharma deal environment in 2026 is as active as it has been in a decade. Indian companies with strong balance sheets, innovative pipelines, or platform capabilities are attractively positioned for cross-border deals — whether as acquirers, acquisition targets, or licensing partners.

**BHC Perspective

At Bengaluru Health Community, the Lilly-Centessa deal is a story that operates on two levels. At the global level, it demonstrates how concentrated cash from one successful drug category can reshape an entire pharmaceutical portfolio strategy — a lesson in the compounding power of breakthrough innovation. At the India level, it signals that the next generation of global drug categories — neurological, sleep, neurodegenerative — will create significant generic and biosimilar opportunities for Indian manufacturers within the next decade. The time to start positioning is now.

**Frequently Asked Questions

Q: What did Eli Lilly acquire from Centessa Pharmaceuticals?
A: Lilly acquired Centessa's pipeline of orexin receptor 2 (OX2R) agonist drugs, led by cleminorexton — an experimental treatment for narcolepsy type 1 and 2 and idiopathic hypersomnia that has shown a potential best-in-class profile in Phase 2a clinical studies.

Q: How much did Eli Lilly pay for Centessa?
A: Lilly agreed to pay $38 per share upfront, valuing Centessa at approximately $6.3 billion, plus up to $9 per share in contingent value rights if specific regulatory milestones are met — making the total potential deal value up to $7.8 billion.

Q: What is an orexin agonist and why does it matter?
A: Orexin agonists modulate the brain's orexin system, which governs the sleep-wake cycle. Beyond narcolepsy and sleep disorders, orexin dysfunction may play a role in Alzheimer's disease, depression, and other neurological conditions — making OX2R agonists a potentially broad platform for neurological medicine.